Z Bhagwagar1, S Hafizi, P J Cowen. 1. University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK.
Abstract
RATIONALE: Intravenous administration of the selective serotonin (5-HT) re-uptake inhibitor, citalopram, increases plasma cortisol. This would be expected to produce a parallel increase in salivary cortisol concentration. OBJECTIVE: To find out whether IV citalopram produces correlated increases in plasma and salivary cortisol levels. METHODS:Twelve healthy volunteers were tested on two occasions receiving either citalopram (10 mg IV) or saline in a double-blind, randomised, cross-over design. Plasma and salivary cortisol levels were measured before and for 150 min after each infusion. RESULTS: Relative to placebo, citalopram significantly increased cortisol levels in both plasma and saliva. The size of the increases in plasma and saliva cortisol correlated significantly with each other. CONCLUSIONS: Monitoring changes in salivary cortisol might be a valid and acceptable means of measuring 5-HT-mediated cortisol release.
RCT Entities:
RATIONALE: Intravenous administration of the selective serotonin (5-HT) re-uptake inhibitor, citalopram, increases plasma cortisol. This would be expected to produce a parallel increase in salivary cortisol concentration. OBJECTIVE: To find out whether IV citalopram produces correlated increases in plasma and salivary cortisol levels. METHODS: Twelve healthy volunteers were tested on two occasions receiving either citalopram (10 mg IV) or saline in a double-blind, randomised, cross-over design. Plasma and salivary cortisol levels were measured before and for 150 min after each infusion. RESULTS: Relative to placebo, citalopram significantly increased cortisol levels in both plasma and saliva. The size of the increases in plasma and saliva cortisol correlated significantly with each other. CONCLUSIONS: Monitoring changes in salivary cortisol might be a valid and acceptable means of measuring 5-HT-mediated cortisol release.
Authors: John G Keilp; Maria A Oquendo; Barbara H Stanley; Ainsley K Burke; Thomas B Cooper; Kevin M Malone; J John Mann Journal: Neuropsychopharmacology Date: 2008-03-19 Impact factor: 7.853
Authors: Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman Journal: Psychopharmacology (Berl) Date: 2004-06-04 Impact factor: 4.530
Authors: Francis E Lotrich; Robert Bies; Matthew F Muldoon; Stephen B Manuck; Gwenn S Smith; Bruce G Pollock Journal: Psychopharmacology (Berl) Date: 2004-09-09 Impact factor: 4.530